BXC BlueLinx Holdings Inc New

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Dermira, Inc. (NASDAQ:DERM), Elanco Animal Health Incorporated (NYSE:ELAN), Ready Capital Corp (NYSE:RC), Cushman & Wakefield PLC (NYSE:CWK), BlueLinx Holdings Inc. (NYSE:BXC), and Lydall, Inc. (NYSE:LDL), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

DERM DOWNLOAD: http://Capital-Review.com/register/?so=DERM ELAN DOWNLOAD: http://Capital-Review.com/register/?so=ELAN RC DOWNLOAD: http://Capital-Review.com/register/?so=RC CWK DOWNLOAD: http://Capital-Review.com/register/?so=CWK BXC DOWNLOAD: http://Capital-Review.com/register/?so=BXC LDL DOWNLOAD: http://Capital-Review.com/register/?so=LDL

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Dermira, Inc. (NASDAQ:DERM), Elanco Animal Health Incorporated (NYSE:ELAN), Ready Capital Corp (NYSE:RC), Cushman & Wakefield PLC (NYSE:CWK), BlueLinx Holdings Inc. (NYSE:BXC), and Lydall, Inc. (NYSE:LDL) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

DERMIRA, INC. (DERM) REPORT OVERVIEW

Dermira's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Dermira reported revenue of $2.24MM vs $1.34MM (up 67.01%) and analysts estimated basic earnings per share -$1.70 vs -$1.46. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Dermira reported revenue of $42.34MM vs $4.54MM (up 832.37%) and analysts estimated basic earnings per share -$5.27 vs -$7.48. Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$1.39. The estimated EPS forecast for the next fiscal year is -$4.33 and is expected to report on February 25th, 2020.

To read the full Dermira, Inc. (DERM) report, download it here: http://Capital-Review.com/register/?so=DERM

-----------------------------------------

ELANCO ANIMAL HEALTH INCORPORATED (ELAN) REPORT OVERVIEW

Elanco Animal Health's Recent Financial Performance

For the twelve months ended December 31st, 2018 vs December 31st, 2017, Elanco Animal Health reported revenue of $3,066.80MM vs $2,889.00MM (up 6.15%) and analysts estimated basic earnings per share $0.28 vs -$1.06. Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The estimated EPS forecast for the next fiscal year is $1.29 and is expected to report on February 5th, 2020.

To read the full Elanco Animal Health Incorporated (ELAN) report, download it here: http://Capital-Review.com/register/?so=ELAN

-----------------------------------------

READY CAPITAL CORP (RC) REPORT OVERVIEW

Ready Capital's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Ready Capital reported revenue of $46.20MM vs $36.14MM (up 27.86%) and analysts estimated basic earnings per share $0.27 vs $0.38 (down 28.95%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Ready Capital reported revenue of $169.50MM vs $138.31MM (up 22.55%) and analysts estimated basic earnings per share $1.84 vs $1.38 (up 33.33%). Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.47. The estimated EPS forecast for the next fiscal year is $1.84 and is expected to report on March 10th, 2020.

To read the full Ready Capital Corp (RC) report, download it here: http://Capital-Review.com/register/?so=RC

-----------------------------------------

CUSHMAN & WAKEFIELD PLC (CWK) REPORT OVERVIEW

Cushman & Wakefield's Recent Financial Performance

For the twelve months ended December 31st, 2018 vs December 31st, 2017, Cushman & Wakefield reported revenue of $8,219.90MM vs $6,923.90MM (up 18.72%) and analysts estimated basic earnings per share -$1.09 vs -$1.54. Analysts expect earnings to be released on May 22nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The estimated EPS forecast for the next fiscal year is $0.90 and is expected to report on February 26th, 2020.

To read the full Cushman & Wakefield PLC (CWK) report, download it here: http://Capital-Review.com/register/?so=CWK

-----------------------------------------

BLUELINX HOLDINGS INC. (BXC) REPORT OVERVIEW

BlueLinx's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, BlueLinx reported revenue of $672.64MM vs $433.61MM (up 55.13%) and analysts estimated basic earnings per share -$1.74 vs $5.90. For the twelve months ended December 31st, 2018 vs December 31st, 2017, BlueLinx reported revenue of $2,862.85MM vs $1,815.54MM (up 57.69%) and analysts estimated basic earnings per share -$5.21 vs $6.96. Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019.

To read the full BlueLinx Holdings Inc. (BXC) report, download it here: http://Capital-Review.com/register/?so=BXC

-----------------------------------------

LYDALL, INC. (LDL) REPORT OVERVIEW

Lydall's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Lydall reported revenue of $209.94MM vs $178.03MM (up 17.92%) and analysts estimated basic earnings per share $0.42 vs $0.80 (down 47.50%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Lydall reported revenue of $785.90MM vs $698.44MM (up 12.52%) and analysts estimated basic earnings per share $2.03 vs $2.89 (down 29.76%). Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.67. The estimated EPS forecast for the next fiscal year is $2.17 and is expected to report on February 24th, 2020.

To read the full Lydall, Inc. (LDL) report, download it here: http://Capital-Review.com/register/?so=LDL

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Morena Zambada, Media Department Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.